Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

ReportsWorldwide has announced the addition of a new report title Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations to its growing collection of premium market research reports.

Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver. Although patients may be asymptomatic for a number of years or decades, chronic HCV infection can lead to liver fibrosis (formation of scar tissue) and ultimately liver cirrhosis, in which permanent fibrotic scar tissue replaces healthy liver cells. In severe cases, cirrhosis may lead to liver failure and death. In addition, hepatitis C patients are at an increased risk of developing liver cancer.

Scope of the Report:

The escalating hepatitis C public healthcare need has resulted in a competitive market landscape

- What is the pathophysiology of hepatitis C?

- What are the common co-morbidities and complications?

- How has the emergence of new drug classes in the past decade impacted the treatment algorithm?

- What are the most significant unmet needs within the market?
The hepatitis C pipeline is relatively large and innovative

- Which molecule types and molecular targets are most prominent within the pipeline?

- Which first-in-class targets are most promising?

- How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

The hepatitis C deals landscape is highly active

- Do hepatitis C products attract high deal values?

- Which molecule types and molecular targets dominate the deals landscape?

- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6859

Reasons to buy

This report will allow you to -

- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.

- Visualize the composition of the hepatitis C market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.

- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to hepatitis C, all first-in-class targets in the hepatitis C pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/frontier-pharma-hepatitis-c-diverse-range-of-first-in-class-host-targeting-and-direct-acting-antivirals-offer-potential-in-difficult-to-treat-populations

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.